Figure 1From: Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancerThe changes in tumor marker levels in case 3 in the first protocol. For case 3, with bone and lymph node metastases, vaccination continued 42 times for 20 months. In this period new metastatic foci did not appear and there was almost no increase in size of the metastatic lesions. Tumor marker levels did not increase rapidly.Back to article page